Anti-CL IgG and IgM are rarely (4.5–5.7 and 6.4–6.6%., respectively) observed in COVID-19 hospitalized patients who are not diagnosed with thrombosis [26,34] but anti-CL IgG and IgM antibodies are present in 52% and 40%, respectively, of COVID-19 patients admitted to intensive care and are highly associated with thrombotic events [96]. The gene discussed is CD40LG; the disease is COVID-19.